JL 13, a potential successor to clozapine, is less sensitive to oxidative phenomena

Biochemical and Biophysical Research Communications

Volumn 238, Issue 1, 1997, Pages 252-255

  Liégeois, Jean François ^a   Mouithys Mickalad, Ange ^a   Bruhwyler, Jacques ^b   Delarge, Jacques ^a   Petit, Christine ^c   Kauffmann, Jean Michel ^c   Lamy, Maurice ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Therabel Pharma Belgium   (Belgium)

^c FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CLOZAPINE; FREE RADICAL; JL 13; LINOLEIC ACID; LOXAPINE; NEUROLEPTIC AGENT; SCAVENGER; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; DRUG POTENCY; DRUG STRUCTURE; ELECTRON SPIN RESONANCE; GAMMA IRRADIATION; LIPID PEROXIDATION; OXIDATION REDUCTION POTENTIAL; PRIORITY JOURNAL;

EID: 0031559876     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.1997.7270     Document Type: Article

References (22)

1. Brunello N., Masotto C., Steardo L., Markstein R., Racagni G. Neuropsychopharmacol. 13:1995;177-213.
2. Kinon B. J., Lieberman J. A. Psychopharmacology. 124:1996;2-34.
3. Liégeois J.-F., Rogister F., Bruhwyler J., Delarge J. Curr. Med. Chem. 1:1995;471-501.
4. Liégeois J.-F., Bruhwyler J., Damas J., Nguyen T. P., Chleide E., Mercier M., Rogister F., Delarge J. J. Med. Chem. 36:1993;2107-2114.
5. Liégeois J.-F., Rogister F., Bruhwyler J., Damas J., Nguyen T. P., Inarejos M. O., Chleide E., Mercier M., Delarge J. J. Med. Chem. 37:1994;519-525.
6. Bruhwyler J., Chleide E., Mercier M. Neurosc. Biobehav. Rev. 14:1990;357-363.
7. Kane J., Honigfeld G., Singer J., Meltzer H. Y. Arch. Gen. Psychiatry. 45:1988;789-796.
8. Pisciotta A. V. Blood Rev. 4:1990;226-237.
9. Bruhwyler J., Liégeois J.-F., Chleide E., Rogister F., Damas J., Delarge J., Mercier M. Behav. Pharmacol. 3:1992;567-579.
10. Bruhwyler J., Liégeois J.-F., Lejeune C., Rogister F., Delarge J., Géczy J. Behav. Pharmacol. 6:1995;830-838.
11. Liégeois J.-F., Bruhwyler J., Damas J., Delarge J., Géczy J. Biol. Psychiatry. 42:1997;44S.
12. Liégeois J.-F., Bruhwyler J., Bergman J., Goudie A., Taylor A., Meltzer H. Y., Géczy J., Delarge J. Pharmacol. Res. 1997.
13. Fischer V., Haar J. A., Greiner L., Lloyd R. V., Mason R. P. Mol. Pharmacol. 40:1991;846-853.
14. Liégeois J.-F., Rogister F., Delarge J., Pincemail J. Arch. Pharm. 328:1995;109-112.
15. Green M. J., Hill H. A. O. Chemistry of Dioxygen. Methods in Enzymology. 105:1984;Academic Press, London. p. 3-22.
16. Walls R., Kumar K. S., Hochstein P. Arch. Biochem. Biophys. 172:1976;463-468.
17. Harman L. S., Carver D. K., Schreiber J., Mason R. P. J. Biol. Chem. 261:1986;1642-1648.
18. Kauffmann J.-M., Vire J.-C., Patriarche G. C. Bioelectrochem. Bioener. 12:1984;413.
19. Sanner M. A., Higgins T. J. Bristol J. A., Michne W. F. Ann. Rep. Med. Chem. 26:1991;181-190 Academic Press, San Diego.
20. Mason R. P., Fischer V. Drug Safety. 7:1992;45-50.
21. Pirmohamed M., Park K. CNS Drugs. 7:1997;139-158.
22. Liu Z. C., Uetrecht J. P. J. Pharmacol. Exp. Ther. 275:1995;1476-1483.